Many patients with NVAF are obese and manage other health conditions requiring multiple medications. This real‐world study compared health care resource use (HRU) and costs for rivaroxaban and ...
Additionally, after an exhaustive analysis of NOACs, analysis showed that apixaban (RR 0.5, 95%CI 0.17–1.46) had a superior performance in major bleeding compared to rivaroxaban (RR 3.87, 95%CI ...